---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028506"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:45:08.354417+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AgeX CEO steps down; cash only $0.3M, substantial doubt about going concern

## Summary
- Net loss $2.7M Q2 2023 ($0.07/sh), consistent YoY; cash $0.3M.
- Juvenescence exchanged $36M debt for preferred shares in July 2023; remaining debt $1.2M.
- CEO Michael West stepped down; Joanne Hackett appointed Interim CEO.
- Jean-Christophe Renondin appointed to Board; possible merger with Serina mentioned.
- Company expresses substantial doubt about ability to continue as going concern.

## SEC filing metadata
- accession: 0001493152-23-028506
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028506
- JSON: https://secwatch.observer/filing/0001493152-23-028506.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028506.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported second quarter 2023 ended June 30, 2023 results: net income $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023, EPS ($0.07) per share (basic and diluted).
  - Period: second quarter 2023 ended June 30, 2023
  - Net income: $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023
  - EPS: ($0.07) per share (basic and diluted)
  - Result: reported results
  source text: the net loss attributable to AgeX for the three months ended June 30, 2023 was $2.7 million, or ($0.07) per share (basic and diluted) compared to $2.6 million, or ($0.07) per share (basic and diluted), for 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.